Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin

Journal of Dermatological Science

Volumn 79, Issue 2, 2015, Pages 163-170

  Barygina, Victoria ^a   Becatti, Matteo ^a   Lotti, Torello ^b   Moretti, Silvia ^c   Taddei, Niccolò ^a   Fiorillo, Claudia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b GUGLIELMO MARCONI UNIVERSITY   (Italy)

^c Departments of Dermatology   (Italy)

Author keywords

Beta endorphin; BFGF; Interleukin 10; Interleukin 4; Perilesional keratinocytes; Vitiligo

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA ENDORPHIN; INTERLEUKIN 10; INTERLEUKIN 4; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; CYTOKINE;

ARTICLE; CELL CYCLE REGULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUOROMETRY; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; KERATINOCYTE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; VITILIGO; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; HUMANS; KERATINOCYTES; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VITILIGO;

EID: 84955727104     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.05.003     Document Type: Article

References (37)

1. Alikhan A., Felsten L.M., Daly M., Petronic-Rosic V. Vitiligo: a comprehensive overview, Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011, 65(3):473-491.
2. Tarlé R.G., Nascimento L.M., Mira M.T., Castro C.C. Vitiligo-Part 1. An Bras Dermatol 2014, 89(3):461-470.
3. Laddha N.C., Dwivedi M., Mansuri M.S., Gani A.R., Ansarullah M., Ramachandran A.V., et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 2013, 22(4):245-250.
4. Dwivedi M., Kemp E.H., Laddha N.C., Mansuri M.S., Weetman A.P., Begum R. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics. Autoimmun Rev 2015, 14(1):49-56.
5. Sandoval-Cruz M., García-Carrasco M., Sánchez-Porras R., Mendoza-Pinto C., Jiménez-Hernández M., Munguía-Realpozo P., et al. Immunopathogenesis of vitiligo. Autoimmun Rev 2011, 10(12):762-765.
6. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
7. Bassiouny D.A., Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011, 36(3):292-297.
8. Prignano F., Pescitelli L., Becatti M., Di Gennaro P., Fiorillo C., Taddei N., et al. Ultrastructural and functional alterations of mitochondria in PL vitiligo skin. J Dermatol Sci 2009, 54(3):157-167.
9. Becatti M., Prignano F., Fiorillo C., Pescitelli L., Nassi P., Lotti T., et al. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: Protective effects of curcumin and capsaicin. Antioxid Redox Signal 2010, 13(9):1309-1321.
10. Roberti M.L., Ricottini L., Capponi A., Sclauzero E., Vicenti P., Fiorentini E., et al. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. J Biol Regul Homeost Agents 2014, 28(1):133-139.
11. Radice E., Miranda V., Bellone G. Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. Int Immunopharmacol 2014, 19(1):66-73.
12. D'Amico L., Ruffini E., Ferracini R., Roato I. Low dose of IL-12 stimulates T cell response in cultures of PBMCs derived from non small cell lung cancer patients. J Cancer Ther 2012, 3(4):337-342.
13. Mozzanica N., Villa M.L., Foppa S., Vignati G., Cattaneo A., Diotti R., et al. Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992, 26(5 Pt 1):693-700.
14. 2-induced oxidative stress. Comp Med 2006, 56(6):493-501.
15. Zhang H.X., Du G.H., Zhang J.T. Assay of mitochondrial functions by resazurin in vitro. Acta Pharmacol Sin 2004, 25:385-389.
16. Takac I., Schröder K., Zhang L., Lardy B., Anilkumar N., Lambeth J.D., et al. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 2011, 286(15):13304-13313.
17. Kumar Mukhopadhyay A. History and evolution of pigmentary disorders in human. Pigmentary disorders: a comprehensive compendium 2014, 1-7. Jaypee Brothers Medical Pub, New Delhi. K. Lahiri, M. Chatterjee, R. Sarkar (Eds.).
18. Lotti T., D'Erme A.M. Vitiligo as a systemic disease. Clin Dermatol 2014, 32(3):430-434.
19. Spritz R.A. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 2012, 132:268-273.
20. Spencer J.D., Gibbons N.C., Rokos H., Peters E.M., Wood J.M., Schallreuter K.U. Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol 2007, 127(2):411-420.
21. Seleit I., Bakry O.A., Abdou A.G., Dawoud N.M. Immunohistochemical expression of aberrant Notch-1 signalling in vitiligo: an implication for pathogenesis. Ann Diagn Pathol 2014, 18:117-124.
22. Moretti S., Fabbri P., Baroni G., Berti S., Bani D., Berti E., et al. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol 2009, 24(7):849-857.
23. Pradhan R., De S., Choudhary N., Mukherjee S., Chatterjee G., Ghosh A., et al. Can systemically generated reactive oxygen species help to monitor disease activity in generalized vitiligo?. A pilot study. Indian J Dermatol 2014, 59(6):547-551.
24. Deo S.S., Bhagat A.R., Shah R.N. Study of oxidative stress in peripheral blood of Indian vitiligo patients. Indian Dermatol Online J 2013, 4(4):279-282.
25. Maresca V., Roccella M., Roccella F., Camera E., Del Porto G., Passi S., et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997, 109:310-313.
26. Colucci R., Böhm M., Moretti S. Commentary from the editorial board to vitiligo: interplay between oxidative stress and immune system (Laddha et al.). Exp Dermatol 2013, 22:397-398.
27. Westerhof W., d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res 2007, 20:345-359.
28. Speeckaert R., Speeckaert M.M., van Geel N. Why treatments do(n't) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev 2015, 14(4):332-340.
29. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 1999, 4(1):91-96.
30. 2/ONOO(-)-mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels. FASEB J 2012, 26(6):2457-2470.
31. 2/ONOO(-)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling. FASEB J 2012, 26(6):2471-2485.
32. Chamulitrat W., Stremmel W., Kawahara T., Rokutan K., Fujii H., Wingler K., et al. A constitutive NADPH oxidase-like system containing gp91phox homologs in human keratinocytes. J Invest Dermatol 2004, 122(4):1000-1009.
33. 2 generation in 3T3 L1-cells. Biochem J 1995, 307(Pt 2):549-556.
34. Caixia T1, Daming Z., Xiran L. Levels of beta-endorphin in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001, 26(1):62-66.
35. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997, 185(3):415-427.
36. Cummins J.M., Krakowka G.S., Thompson C.G. Systemic effect of interferons after oral administration in animals and humans. Am J Vet Res 2005, 66(1):164-176.
37. Brod S.A., Khan M. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun 1996, 9(1):11-20.